AGI-5198 is a potent and selective inhibitor of IDH1 R132H and R132C mutants with IC50 values of 0.07 and 0.16 µM, respectively, but not wild-type IDH1, wild-type IDH2, or IDH2 mutants.

Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.

Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 μM.

Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.

Olutasidenib是一种口服有效的IDH1抑制剂，能够透过血脑屏障，对IDH1-R132H和IDH1-R132C突变型具有显著的抑制作用。它在急性髓性白血病和骨髓增生异常综合征的研究中展现出潜力。

AG-120 Racemate is the racemate form of AG-120 with no activity.

AGI-6780 is a selective inhibitor of IDH2/R140Q mutant with IC50 value of 23 nM,

BAY 1436032 is a potent, selective and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1).

DS-1001b is a novel selective mutant IDH1 inhibitor with antitumor activity.

IDH-305 is a selective inhibitor of IDH1 R132H and R132C with IC50 of 18 and 28 nM, respectively.

Vorasidenib is an isocitrate dehydrogenase (IDH) inhibitor.

Ivosidenib 是一种选择性的 IDH1（异柠檬酸脱氢酶 1）抑制剂，对 IDH1 R132H 突变体具有高亲和力。Ivosidenib 主要用于治疗具有 IDH1 突变的急性髓性白血病 (AML) 和其他相关肿瘤。

Enasidenib is a selective mutant IDH2 enzyme inhibitor with IC50 of 12 nM.

D-alpha-Hydroxyglutaric Acid Disodium is a multiple-target inhibitor of KDM4A and α-Ketoglutarate(α-KG)-dependent dioxygenase, as well as an NF-κB activator.